CytoSorbents Reports Third Quarter 2023 Financial and Operational Results

Q3 2023 Product sales grew 20% to $7.8M versus $6.5M in Q3 2022. Q3 2023 Total revenue was approximately $8.8M. The pivotal STAR-T trial remains blinded with database lock nearing and initial data analysis completion expected before year-end.PRINCETON, N.J., Nov. 09, 2023 (GLOBE NEWSWIRE) -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification via its proprietary polymer adsorptio

Related Keywords

Canada ,State Of New Jersey ,New Jersey ,United States ,Germany ,New York ,American ,Canadian ,Kathleen Bloch ,Vincent Capponi ,James Komsa ,Phillip Chan ,Irina Kulinets ,Efthymios Deliargyris ,Health Canada ,National Heart ,Bus Company Contact ,Fresenius ,Development Expenses ,Us Centers Of Medicare Medicaid Services ,National Institutes Of Health ,Human Services ,Cytosorbents Corporation ,Blood Institute ,Facebook ,Pfizer ,Material Command ,Us Department Of Health ,European Union ,Us Army ,Us Air ,Medtronic ,Vascular Group ,Fresenius Medical Care ,Company Board Of Directors ,Astrazeneca ,Sorbents Corporation ,Operating Highlights ,Chief Executive Officer ,Timely Antithrombotic Removal ,Safety Monitoring Board ,Global Regulatory ,Device Designation ,American Journal ,Cardiovascular Drugs ,Quality Star Rating ,Medicaid Services ,Chief Operating Officer ,Chief Medical Officer ,Vice President ,Northeast Cardiac ,Critical Care ,Blood Purification ,Medical Care ,Acute Therapies ,Renal Therapies ,Administrative Expenses ,Foreign Currency Transactions ,Capital Resources ,Call Details ,Presentation Webcast ,Investor Relations ,Use Authorization ,Device Designations ,Timely Antithrombotic Removal Ticagrelor ,National Institutes ,Operations Command ,Air Force Material Command ,Private Securities Litigation Reform Act ,Annual Report ,Quarterly Reports ,Cardiac Surgery ,Cardiothoracic Surgery ,Product Sales ,Total Revenue ,